Menu

Prescribing guidelines

Loading…

Clinical support by body system

Conditions and indicators

Alcohol dependence1
Allergic rhinitis1
Angina pectoris1
Antiplatelets1
Asthma2
Atrial fibrillation1
Cancer : Palliative care1
Depression2
Dysphagia1
Epilepsy3
Heart failure4
Incontinence2
Inflammatory Bowel Disease1
Neuropathic pain1
Obesity and bariatric surgery1
Osteoporosis2
Pain management6
Peptic ulcers1
Rheumatoid arthritis1
Stroke2
Substance dependence1
Transient Ischaemic Attack TIA1
Type 1 Diabetes2
Type 2 Diabetes2

Traffic light

April 2022 - APC Approved list of guideline review date extensions (to 3 years from date approved)

1
2
3
4
5
6
7
8
9
10
Next
Last

GU: OAB- OverActive Bladder in Women (APC Approved)

Women's and Sexual Health

Over active bladder in women
GU: Sildenafil- QIPP

Renal, Urology and Mens Health
GU: Trial of Stopping Your Overactive Bladder Drug Patient Information Leaflet (APC Approved)

Renal, Urology and Mens Health
GU:CKD chronic Kidney disease pathway
Interim Position Statement for Tirzepatide for managing overweight and obesity (IMOC approved)

Endocrine and Diabetes
Lab: Hypomagnesaemia
Lab: Iron Deficiency Anaemia Pathway (APC Approved)
Lab: Vitamin B Co and Vitamin B Co Strong (APC Approved)

Endocrine and Diabetes Laboratory investigations and Infections
Meds : Specials: Unlicensed specials (APC Approved)
Meds: Items which should not be routinely prescribed

1
2
3
4
5
6
7
8
9
10
Next
Last

Did you find this page helpful?